RenovoRx rises on positive data from pancreatic cancer therapy study

RenovoRx

29/06/2023 13:40

** Shares of drug developer RenovoRx Inc  RNXT.O  rise 25%
to $2.80 premarket  
    ** Co says its experimental therapy to treat advanced 
pancreatic cancer delayed disease progression, according to
interim data from a late-stage study   
    ** The therapy, RenovoGem, delayed cancer progression by 15
months compared to 7 months in standard-of-care treatment- RNXT
    ** RenovoGem is RNXT's first drug-device combination product
candidate that utilizes company's therapy platform to deliver an
FDA-approved chemotherapy
    ** Up to last close, stock down ~5% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))